Failure of an Innovative Low-Cost, Noninvasive Thermotherapy Device for Treating Cutaneous Leishmaniasis Caused by in Pakistan.
MetadataShow full item record
AbstractCutaneous leishmaniasis (CL), a neglected parasitic skin disease, is endemic in Pakistan, where Leishmania tropica and Leishmania major are the causative protozoan species. Standard treatment with antimonial injections is long, painful, and costly; has toxic side effects; and is not always available in public hospitals. Small pilot studies have previously evaluated a low-cost and noninvasive hand-held exothermic crystallization thermotherapy (HECT-CL) device. We aimed to further establish the effectiveness, safety, and feasibility of HECT-CL in L. tropica. In a prospective observational study, patients with parasitological confirmation of CL were treated using the HECT-CL heat pack for 3 minutes with an initial temperature of 52-53°C for 7 consecutive days. Dried blood spot samples were taken for species identification by PCR. Effectiveness was assessed by using medical photographs and measurements of the lesion size at baseline and subsequent follow-up visits, for up to 180 days. We intended to enroll 317 patients. The HECT-CL treatment was easy to apply and well tolerated. Species identification demonstrated the presence of L. tropica. Interim analysis of 56 patients showed a failure rate of 91% at follow-up (median 45 days after treatment, interquartile range 30-60 days). Enrollment of patients was prematurely suspended because of futility. This study showed a high failure rate for HECT-CL thermotherapy in this setting. Leishmania tropica is known to be less sensitive to antileishmanial drugs, more temperature-resistant, and spontaneous healing is slower than that in L. major. More research is needed to identify low-cost, effective, and more patient-friendly treatment for L. tropica.
- Cutaneous leishmaniasis caused by Leishmania (L.) major infection in Sindh province, Pakistan.
- Authors: Bhutto AM, Soomro FR, Baloch JH, Matsumoto J, Uezato H, Hashiguchi Y, Katakura K
- Issue date: 2009 Sep
- Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica.
- Authors: Solomon M, Pavlotsky F, Leshem E, Ephros M, Trau H, Schwartz E
- Issue date: 2011 Aug
- EAPB0503: An Imiquimod analog with potent in vitro activity against cutaneous leishmaniasis caused by Leishmania major and Leishmania tropica.
- Authors: El Hajj R, Bou Youness H, Lachaud L, Bastien P, Masquefa C, Bonnet PA, El Hajj H, Khalifeh I
- Issue date: 2018 Nov
- Prevalence of Leishmania species among patients with cutaneous leishmaniasis in Qassim province of Saudi Arabia.
- Authors: Rasheed Z, Ahmed AA, Salem T, Al-Dhubaibi MS, Al Robaee AA, Alzolibani AA
- Issue date: 2019 Apr 5
- Detection, genotyping, and phylogenetic analysis of Leishmania isolates collected from infected Jordanian residents and Syrian refugees who suffered from cutaneous leishmaniasis.
- Authors: Hijawi KJF, Hijjawi NS, Ibbini JH
- Issue date: 2019 Mar